ArticleFrontiers in psychiatry2025
The relationship between cognitive function and cortical thickness in first-episode drug-naive schizophrenia patients with agitation.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to explore the relationships between the agitation behavior, cognitive function and cortical thickness in first-episode drug-naïve schizophrenia (FESN). Methods: A total of 55 male healthy controls (HC) and 79 male inpatients with FESN were enrolled in the present study. Whole brain cortical thickness was extracted from T1-weighted MRI using Freesurfer Version 7.4.1 software package. Cognitive function was evaluated using the MATRICS Consensus Cognitive Battery (MCCB). The Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) is used to divide these inpatients into agitation group (FESN+A) and non-agitation group (FESN+NA). Correlation analysis was employed to investigate the potential associations between cortical thickness and cognitive function. Results: The FESN+A group had higher Positive and Negative Syndrome Scale (PANSS) total score, positive symptom score, and general psychopathology score than the FESN+NA group. Both the FESN+A/NA groups showed significantly worse performance than the HC in symbol coding, working memory, attention/vigilance, reasoning and problem solving, and social cognition. The FESN+A group performed worse on working memory when comparing to FESN+NA group. Furthermore, the cortical thickness of the left paracalcarine gyrus was increased in the FESN+NA group, compared to HC. FESN+A group had thicker cortical thickness in the right posterior cingulate cortex (rPCC) compared with the FESN+NA group. The cortical thickness of rPCC was negatively correlated with score of working memory in the FESN+A group. Conclusion: The present study demonstrated that the abnormal cortical thickness of rPCC may be related to the agitation behavior and cognitive function in patients with FESN+A, suggesting a potential treatment target for agitation behavior and cognitive impairment in schizophrenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.